Table 4. Endocrine vs chemoendocrine: second non-breast primaries as sites of first failure (Trials III, VII, and the first 212 patients in Trial 12).

	Endocrine		Chemoendocrine		TOTAL
Total patients	529	(100.0%)	1202	(100.0%)	1731	(100.0%)
Total patients with second non-breast primary cancer	46	(8.7%)	93	(8.0%)	139	(8.0%)
14-year cumulative incidence of second non-breast cancer*	6.5%		7.2%		7.0%
(95% confidence interval)	(4.3%, 8.6%)		(5.6%, 8.7%)		(5.7%,8.2%)
Types of second non-breast cancer
Head and Neck	2	(0.4%)	1	(<0.1%)	3	(0.2%)
Thyroid	1	(0.2%)	3	(0.2%)	4	(0.2%)
Lung (non small cell)	.		3	(0.2%)	3	(0.2%)
Lung (type not specified)	.		5	(0.4%)	5	(0.3%)
Lung carcinoid	1	(0.2%)	.		1	(<0.1%)
Esophageal	.		3	(0.2%)	3	(0.2%)
Gastric	6	(1.1%)	5	(0.4%)	11	(0.6%)
Small bowel	.		1	(<0.1%)	1	(<0.1%)
Colon	5	(0.9%)	7	(0.6%)	12	(0.7%)
Rectal	4	(0.8%)	3	(0.2%)	7	(0.4%)
Pancreatic	1	(0.2%)	5	(0.4%)	6	(0.3%)
Hepatic	.		1	(<0.1%)	1	(<0.1%)
Biliary	1	(0.2%)	1	(<0.1%)	2	(0.1%)
Colorectal (type not specified)	.		1	(<0.1%)	1	(<0.1%)
Renal	1	(0.2%)	3	(0.2%)	4	(0.2%)
Urothelial	2	(0.4%)	7	(0.6%)	9	(0.5%)
Ovarian	3	(0.6%)	6	(0.5%)	9	(0.5%)
Endometrial	5	(0.9%)	16	(1.3%)	21	(1.2%)
Mixed Muellerian tumor	1	(0.2%)	2	(0.2%)	3	(0.2%)
Uterine sarcoma	.		1	(<0.1%)	1	(<0.1%)
Uterine (type not specified)	.		1	(<0.1%)	1	(<0.1%)
Cervical	2	(0.4%)	2	(0.2%)	4	(0.2%)
Vulvar	.		1	(<0.1%)	1	(<0.1%)
Central nervous system (type not specified)	1	(0.2%)	.		1	(<0.1%)
Melanoma	4	(0.8%)	4	(0.3%)	8	(0.5%)
Ocular melanoma	.		1	(<0.1%)	1	(<0.1%)
Acute lymphocytic leukaemia	.		1	(<0.1%)	1	(<0.1%)
Acute myeloid leukaemia	1	(0.2%)	1	(<0.1%)	2	(0.1%)
Chronic lymphocyticleukaemia	.		2	(0.2%)	2	(0.1%)
Non-Hodgkin's lymphoma	3	(0.6%)	4	(0.3%)	7	(0.4%)
Lymphoma (type not specified)	1	(0.2%)	1	(<0.1%)	2	(0.1%)
Multiple myeloma	1	(0.2%)	.		1	(<0.1%)
Primary peritoneal	.		1	(<0.1%)	1	(<0.1%)

^*Competing risk analysis [13]